首页> 美国卫生研究院文献>Genes >Preimplantation Genetic Testing for Polygenic Disease Relative Risk Reduction: Evaluation of Genomic Index Performance in 11883 Adult Sibling Pairs
【2h】

Preimplantation Genetic Testing for Polygenic Disease Relative Risk Reduction: Evaluation of Genomic Index Performance in 11883 Adult Sibling Pairs

机译:多基因疾病相对风险降低的植入前基因测试:对11883个成年同胞对的基因组指数性能的评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Preimplantation genetic testing for polygenic disease risk (PGT-P) represents a new tool to aid in embryo selection. Previous studies demonstrated the ability to obtain necessary genotypes in the embryo with accuracy equivalent to in adults. When applied to select adult siblings with known type I diabetes status, a reduction in disease incidence of 45–72% compared to random selection was achieved. This study extends analysis to 11,883 sibling pairs to evaluate clinical utility of embryo selection with PGT-P. Results demonstrate simultaneous relative risk reduction of all diseases tested in parallel, which included diabetes, cancer, and heart disease, and indicate applicability beyond patients with a known family history of disease.
机译:植入前基因测试的多基因疾病风险(PGT-P)代表了一种新的工具,可以帮助选择胚胎。先前的研究证明了在胚胎中获得必需基因型的能力,其准确性与成年人相同。当用于选择患有已知I型糖尿病状态的成年兄弟姐妹时,与随机选择相比,疾病发病率降低了45–72%。这项研究将分析扩展到11883个同胞对,以评估PGT-P选胚的临床效用。结果表明,并行测试的所有疾病(包括糖尿病,癌症和心脏病)的同时相对危险度降低,并且表明其适用范围超出已知疾病家族史的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号